{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:22:43Z","timestamp":1794241363504,"version":"4.9.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jhepr.2026.102041","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:14:02Z","timestamp":1789722842000},"page":"102041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aligned ELF and VCTE cut-offs facilitate risk staging in patients with metabolic dysfunction-associated steatohepatitis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3931-0625","authenticated-orcid":false,"given":"Matthew F.W.","family":"Gee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7752-0934","authenticated-orcid":false,"given":"Andrew N.","family":"Billin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-3095","authenticated-orcid":false,"given":"Donald B.","family":"Chalfin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Fonstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-128X","authenticated-orcid":false,"given":"Edward B.","family":"De Vol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2211","authenticated-orcid":false,"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-3127","authenticated-orcid":false,"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhepr.2026.102041_bib1","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/hep.28677","article-title":"Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort","volume":"64","author":"Setiawan","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102041_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102041_bib3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European association for the study of diabetes (EASD), European association for the study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102041_bib4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhepr.2026.102041_bib5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102041_bib6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102041_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102041_bib8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most Rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102041_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102041_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1373\/jalm.2018.027359","article-title":"Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and Prognosis of liver fibrosis","volume":"3","author":"Day","year":"2019","journal-title":"J Appl Lab Med"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"Mozes","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102041_bib14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/HEP.0000000000000842","article-title":"Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline","volume":"81","author":"Patel","year":"2025","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jhepr.2026.102041_bib15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/sim.1185","article-title":"Exploring sources of heterogeneity in systematic reviews of diagnostic tests","volume":"21","author":"Lijmer","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.jhepr.2026.102041_bib16","series-title":"Cochrane Handbook for systematic reviews of diagnostic test Accuracy","article-title":"Chapter 10: Analysing and presenting results","author":"Macaskill","year":"2010"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102041_bib17","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102041_bib18","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.cgh.2020.06.070","article-title":"Enhanced liver fibrosis score can Be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis","volume":"19","author":"Are","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib19","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with Adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102041_bib20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep4.1852","article-title":"Predicting liver-related outcomes in People with nonalcoholic fatty liver disease: the prognostic value of noninvasive fibrosis tests","volume":"6","author":"Johnson","year":"2022","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib21","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102041_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/gutjnl-2022-327777","article-title":"Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis","volume":"72","author":"Loomba","year":"2023","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.jhepr.2026.102041_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"Mozes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102041_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with Long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102041_bib25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.jhepr.2026.102041_bib26","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in Adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib27","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2024.06.008","article-title":"Liver biopsy evaluation in MASH drug development: Think thrice, act wise","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib28","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102041_bib29","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab is Ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102041_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102041_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including Cilofexor and Firsocostat for bridging fibrosis and cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib32","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102041_bib33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102041_bib34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12876-021-01795-5","article-title":"The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study","volume":"21","author":"Connoley","year":"2021","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib35","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000931","article-title":"Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH","volume":"10","author":"Gee","year":"2026","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102041_bib36","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102041_bib38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice Update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102041_bib39","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel","year":"2020","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102041_bib40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102041_bib41","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance","author":"Bansal","year":"2025","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.jhepr.2026.102041_bib42","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of Semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102041_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102041_bib44","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.31687","article-title":"Nonalcoholic steatohepatitis: current Thinking from the Division of Hepatology and Nutrition at the Food and drug Administration","volume":"73","author":"Anania","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102041_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/HEP.0000000000001509","article-title":"Non-invasive tests: Establishing efficacy for metabolic dysfunction-associated steatohepatitis beyond the biopsy-current perspectives from the Division of Hepatology and Nutrition, US Food and drug Administration","volume":"84","author":"Anania","year":"2025","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102041_bib46","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: a prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102041_bib47","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2026.102041_bib48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102041_bib49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","article-title":"Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores","volume":"78","author":"Sanyal","year":"2023","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926003125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:29:44Z","timestamp":1794238184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926003125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2589555926003125"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102041","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aligned ELF and VCTE cut-offs facilitate risk staging in patients with metabolic dysfunction-associated steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102041"}}